Cochrane · systematic review · CD011501
Brivaracetam add‐on therapy for drug‐resistant epilepsy
Bresnahan, R, Panebianco, M, Marson, AG · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
5
current version
GRADE rated
5
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 3 · 60%Moderate 2 · 40%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 2 versionsBrivaracetam compared to placebo as add‐on therapy for focal epilepsy
Population: people with drug‐resistant focal epilepsy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
50% or greater reduction in seizure frequency (responder rate) Brivaracetam vs placebo | RR 1.81 [1.53, 2.14] | 6 studies · 2411 participants | Moderate Downgraded: risk of bias |
Seizure freedom Brivaracetam vs placebo | RR 5.89 [2.3, 15.13] | 6 studies · 2411 participants | Low Downgraded: risk of bias, imprecision |
Treatment withdrawal Brivaracetam vs placebo | RR 1.27 [0.94, 1.74] | 6 studies · 2411 participants | Low Downgraded: risk of bias, imprecision |
Proportion of participants who experienced adverse events leading to treatment withdrawal Brivaracetam vs placebo | RR 1.54 [1.02, 2.33] | 6 studies · 2411 participants | Low Downgraded: risk of bias, imprecision |
Proportion of participants who experienced any adverse events Brivaracetam vs placebo | RR 1.08 [1, 1.17] | 5 studies · 2011 participants | Moderate Downgraded: risk of bias |